Kymera Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD). Founded in 2016 and headquartered in Watertown, Massachusetts, the company leverages its proprietary Pegasus™ platform to design and develop novel small molecule degraders. These therapies are engineered to selectively eliminate disease-causing proteins by harnessing the body's natural ubiquitin-proteasome system. Kymera's pipeline is primarily focused on immunology-inflammation and oncology, with key clinical-stage programs including KT-621 (an oral STAT6 degrader), KT-579 (an oral IRF5 degrader), and partnered programs such as KT-485/SAR447971 (an oral IRAK4 degrader developed with Sanofi) and CDK2 degraders (partnered with Gilead Sciences).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing a pipeline of highly selective, oral small molecule protein degraders targeting key immunological pathways (such as STAT6 and IRF5) to deliver biologics-like efficacy and safety with the convenience of oral dosing.
Expected impact: Aims to establish first-in-class oral therapies that transform treatment paradigms for patients with moderate-to-severe inflammatory and autoimmune diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High
Terms: Kymera received $40 million upfront in June 2025. In April 2026, Gilead exercised its option to exclusively license the oral CDK2 molecular glue degrader KT-200, triggering a $45 million milestone payment. Kymera is eligible to receive up to $665 million in additional development, regulatory, and commercial milestones, plus tiered royalties ranging from high single-digit to mid-teens on net sales.
High
Terms: Kymera received a $150 million upfront cash payment. Kymera is eligible to receive more than $2 billion in potential development, regulatory, and sales milestones, as well as significant royalty payments. For the KT-485 (SAR447971) IRAK4 program, Kymera is eligible for up to $975 million in clinical, regulatory, and commercial milestones.